Benitec Biopharma Inc. (BNTC) Current Ratio
- Current ratio · latest quarter: Value 34.00×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 34.00× | Current assets / current liabilities. $181.69M ÷ $5.34M ≈ 34.00× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 181.69M USD | Assets, Current |
| Current obligations | 5.34M USD | Liabilities, Current |
| Cash and equivalents | 179.97M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | (m) | |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $181.69M | $5.34M | $179.97M | (m) | (m) | (m) | (m) | (m) | 34.00× |
| 2026-03-31 | $186.02M | $3.27M | $184.76M | (m) | (m) | (m) | (m) | (m) | 56.82× |
| 2025-12-31 | $189.59M | $2.80M | $188.79M | (m) | (m) | (m) | (m) | (m) | 67.69× |
| 2025-09-30 | $95.08M | $2.02M | $94.48M | (m) | (m) | (m) | (m) | (m) | 46.95× |
| 2025-06-30 | $98.52M | $1.80M | $97.74M | (m) | (m) | (m) | (m) | (m) | 54.67× |
| 2025-03-31 | $104.01M | $7.03M | $103.58M | (m) | (m) | (m) | (m) | (m) | 14.80× |
| 2024-12-31 | $78.71M | $3.09M | $78.28M | (m) | (m) | (m) | (m) | (m) | 25.48× |
| 2024-09-30 | $68.33M | $4.55M | $67.84M | (m) | (m) | (m) | (m) | (m) | 15.01× |
| 2024-06-30 | $51.67M | $4.92M | $50.87M | (m) | (m) | (m) | (m) | (m) | 10.49× |
| 2024-03-31 | $14.37M | $3.44M | $14.10M | (m) | (m) | (m) | (m) | (m) | 4.18× |
| 2023-12-31 | $20.80M | $5.75M | $20.37M | (m) | (m) | (m) | (m) | (m) | 3.62× |
| 2023-09-30 | $26.41M | $4.53M | $25.86M | (m) | (m) | (m) | (m) | (m) | 5.83× |
| 2023-06-30 | $3.73M | $3.98M | $2.48M | (m) | (m) | (m) | (m) | (m) | 0.94× |
| 2023-03-31 | $7.39M | $3.15M | $6.55M | (m) | (m) | (m) | (m) | (m) | 2.35× |
| 2022-12-31 | $10.97M | $2.49M | $10.54M | (m) | (m) | (m) | (m) | (m) | 4.41× |
| 2022-09-30 | $17.08M | $3.01M | $16.53M | (m) | (m) | (m) | (m) | (m) | 5.67× |
| 2022-06-30 | $4.82M | $2.53M | $4.06M | (m) | (m) | (m) | (m) | (m) | 1.90× |
| 2022-03-31 | $8.84M | $1.91M | $8.63M | (m) | (m) | (m) | (m) | (m) | 4.63× |
| 2021-12-31 | $12.67M | $2.48M | $12.33M | (m) | (m) | (m) | (m) | (m) | 5.11× |
| 2021-09-30 | $16.37M | $1.60M | $15.73M | (m) | (m) | (m) | (m) | (m) | 10.23× |
| 2021-06-30 | $20.61M | $1.37M | $19.77M | (m) | (m) | (m) | (m) | (m) | 15.05× |
| 2021-03-31 | $12.41M | $2.44M | $11.99M | (m) | (m) | (m) | (m) | (m) | 5.08× |
| 2020-12-31 | $14.38M | $779.00K | $14.01M | (m) | (m) | (m) | (m) | (m) | 18.46× |
| 2020-09-30 | $8.06M | $1.02M | $7.45M | (m) | (m) | (m) | (m) | (m) | 7.91× |
| 2020-06-30 | $10.81M | $1.14M | $9.80M | (m) | (m) | (m) | (m) | (m) | 9.51× |
| 2019-06-30 | $18.76M | $2.64M | $15.72M | (m) | (m) | (m) | (m) | (m) | 7.10× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |